Scrip
UCB's anti-epileptic Vimpat ready for US launch
28 May 2009
Sue Sutter
Please Login to read the full article.
28 May 2009
Sue Sutter
UCB's anti-epileptic Vimpat (lacosamide) will be available in US pharmacies by the first week of June now that the Drug Enforcement Administration (DEA) has finalised its classification as a schedule V controlled substance.
The
FDA approved Vimpat in October as adjunctive therapy for partial...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
SCIENCE
- Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial
- Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial
EVENTS
Today
Berlin, Germany
Today
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
